Dry Eye – Current Treatment – Current Treatment: Physician Insights – Dry Eye Disease (EU3)
Dry eye disease (DED) is characterized by the loss of tear film homeostasis, caused by the inadequate production or the rapid evaporation of tears. In Europe, DED has traditionally been managed with over-the-counter artificial tears to maintain ocular lubrication and off-label ophthalmic corticosteroids for rapid symptom relief, as well as nonpharmacological interventions such as device-assisted therapies, intense pulse light laser treatment, and surgical procedures (e.g., punctal occlusion). Apart from Rayner’s ilube in the United Kingdom, Santen’s Ikervis has been the only approved treatment for DED in Europe. However, due to its narrow indication—severe keratitis in adult DED patients unresponsive to tear substitutes—Ikervis is reserved for eligible patients. In this report, we discuss European ophthalmologists’ prescribing practices and the key factors influencing their choice of therapy for DED.
QUESTIONS ANSWERED
- What are the drivers and constraints influencing physicians’ treatment decisions for DED?
- How are DED patients being managed across different lines of therapy?
- What patient share does Ikervis capture in DED?
- How are nonpharmacological approaches integrated in the treatment algorithm for DED in each of the EU3 countries?
GEOGRAPHY
- Italy, Spain, United Kingdom
PRODUCT DESCRIPTION
Through survey data from EU3 physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:
- Understand the treatment landscape for a disease and how physicians make prescribing decisions.
- Evaluate the drivers and obstacles that influence treatment selection.
- Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.
